Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients

Clinical Transplantation

Volumn 11, Issue 6, 1997, Pages 577-581

  Kaijser, Magnus ^a   Johnsson, Cecilia ^a   Zezina, Lilija ^a   Backman, Ulla ^a   Dimény, Emöke ^a   Fellström, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carvedilol; Cyclosporine; Interaction; Renal transplant

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ATENOLOL; CARBAZOLES; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPANOLAMINES; VASODILATOR AGENTS;

EID: 0030721683     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. FELLSTRÖM B, LARSSON E. Pathogenesis and treatment perspectives of chronic graft rejection. Immunol Rev 1993: 134: 83.
2. PAUL LC, FELLSTROM E. Chronic vascular rejection of the heart and the kidney - Have rational treatment options emerged? Transplantation 1992: 53: 1169.
3. FAULK PW, LABARRERE CA. Vascular immunopathology and atheroma development in human allografted organs. Arch Pathol Lab Med 1992: 116: 1337.
4. FELLSTRÖM B, LARSSON E, TUFVESON G. Strategies in chronic rejection of transplanted organs: A current view on pathogenesis, diagnosis, and treatment. Transpl Proc 1989: 21: 1435.
5. STRONG JP. Atherosclerotic lesions. Natural history, risk factors, and topography. Arch Pathol Lab Med 1992: 116: 1268.
6. GELLAI M, DEWOLF R, RUFFOLO RR. Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats. Pharmacology 1990: 41: 200.
7. YUE TL, MCKENNA PJ, RUFFOLO RR, FEUERSTEIN F. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992: 214: 277.
8. SUNG CP, ARLETH AJ, OHLSTEIN EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993: 21: 221.
9. YUE TL, CHENG HY, LYSKO PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992: 263: 92.
10. YUE TL, TIU L, FEUERSTEIN G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992: 1: 27
11. YUE TL, MCKENNA PJ, LYSKO PG, RUFFOLO RR, FEUERSTEIN GZ. Carvedilol, a new antihypertensive, prevents oxidation of human LDL by macrophages and copper. Atherosclerosis 1992: 97: 209.
12. WAGNER K, HENKEL M, HEINEMEYER G, NEUMAYER HH. Interaction of calciumblockers and cyclosporine. Transpl Proc 1988: 20: 561.
13. WADHWA NK, SCHROEDER TJ, O'FLAHERTY E, PESCE AJ, MYRE SA, FIRST MR. The effect of oral metoclopramide on the absorption oc cyclosporine. Transplantation 1987: 43: 211.
14. GORRIE M, BEAMAN M, NICHOLLS A, BACKWELL P. Allopurinol interaction with cyclosporine. Br Med J 1994: 308: 113.
15. JAROWENKO MV, VAN BUREN CT, KRAMER WG, LOFBEER MI, FLECHNER SM, KAHAN BD. Ranitidine, cimetidine, and the cyclosporine-treated patient. Transplantation 1986: 42: 311.
16. THOMSON DJ, MENKIS AH, MCKENZIE FN. Norfloxacin-Cyclosporine interaction. Transplantation 1988: 46: 312.
17. KRONBACH T, FISCHER V, MEYER UA. Cyclosporine metabolism in human liver: identification of a cytochrome p-450111 gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988: 43: 630.
18. FUJIMAKI M. Oxidation of R(+) and S(-) carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P 450 isozymes involved. Drug Metab Disp 1994: 22: 700.
19. GED C, ROUILLON JM, PICHARD L, et al. The increase of urinary excretion of 6-beta- hydrocortisol as a marker of human hepatic cytochrome P450 3A. Br J Clin Pharmacol 1989: 28: 373.
20. RUFFOLO RR, BOYLE DA, BROOKS DP, et al. Carvedilol: A novel cardivascular drug with multiple actions. Cardivasc Drug Rev 1992: 10: 127.